此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一组细菌基因标记 (M3) 对结直肠晚期肿瘤的诊断准确性 (M3-PRO)

2026年9月21日 更新者:Louis Ho Shing Lau、Chinese University of Hong Kong

一项前瞻性横断面研究,以评估一组细菌基因标记 (M3) 对结直肠晚期肿瘤的诊断准确性

The investigators aim to evaluate and compare the diagnostic accuracy of FIT and the novel panel of bacterial gene markers (Fn, m3, Ch and Bc) collectively named as M3, in detecting colorectal advanced neoplasia.

研究概览

详细说明

Colorectal cancer (CRC) is the one of the most common cancers in Hong Kong with more than 5,500 new cases annually. There is prevailing evidence of increasing trend of young onset CRC globally. Early detection and resection of pre-malignant colorectal neoplasia has shown to reduce CRC-related mortality.

Non-invasive stool tests including guaiac-based faecal occult blood tests (gFOBT) and faecal immunochemical tests (FIT) are the cornerstones of population-based CRC screening programmes. The major limitation of this widely used strategy is its unsatisfactory sensitivities for CRC (79%) and advanced adenomas (AA; 40%). The sensitivity for non-advanced adenomas is even lower than 10%. A large proportion of advanced and non-advanced adenomas will be missed by FIT alone. Therefore, identification of alternative non-invasive test with better sensitivity to detect colorectal neoplasia is warranted.

Multitarget stool DNA test and faecal microbial DNA markers appear to be promising options for CRC screening. Several bacterial gene markers have been identified by metagenome sequencing and reported to be associated with CRC, including Fusobacterium nucleatum (Fn), Clostridium hathewayi (Ch) and Bacteroides clarus (Bc). However, these molecular markers had low accuracy in distinguishing adenomas from normal tissue. Recently, a new Lachnoclostridium gene marker (labelled as 'm3') has been shown to have high diagnostic yield for the detection of colorectal adenomas. In a case-control study of 1012 subjects, a linear increasing trend of m3 level was observed from fecal samples of healthy subjects to those with adenomas and cancers. The overall sensitivity of m3 was significantly higher than FIT in detecting all adenomas (48% vs 9.3%), AA (50.8% vs 16.1%) and non-advanced adenomas (44.2% vs 0%). The diagnostic accuracy of m3 could be further enhanced by combining with a panel of fecal microbial markers composing of Fusobacterium nucleatum (Fn), Bacteroides clarus (Bc), Clostridium hathewayi (Ch) for CRC (82.3%) and adenomas (64.2%). We hypothesized that the combination of these 4 bacterial gene markers (known as M3) is more sensitive than FIT in detecting colorectal advanced neoplasia.

研究类型

观察性的

注册 (估计的)

2500

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Hong Kong、香港
        • Prince of Wales Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Subjects with average risk of colorectal neoplsia requring screening/surveillance colonoscopy

描述

Inclusion Criteria:

  1. They require elective colonoscopy for colorectal cancer screening or polyp surveillance, or investigation of symptoms (e.g. anemia, change of bowel habit, abdominal pain);
  2. Aged ≥18 years old;
  3. Written informed consent obtained.

Exclusion Criteria:

  1. Contraindications to colonoscopy (e.g. perforation, intestinal obstruction, unstable cardiopulmonary status);
  2. Contraindication to polyp resection (e.g. active gastrointestinal bleeding, uninterrupted anticoagulation or dual antiplatelets);
  3. Known colorectal cancer or adenoma for staged procedure;
  4. Previous colonic resection;
  5. Personal history of colorectal cancer;
  6. Personal history of polyposis syndrome;
  7. Personal history of inflammatory bowel disease;
  8. Known pregnancy or lactation;
  9. Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4 or above);

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:CASE_ONLY
  • 时间观点:CROSS_SECTIONAL

队列和干预

团体/队列
干预/治疗
Colorectal neoplasia screening/surveillance cohort

Subjects with average risk of colorectal neoplasias requiring screening/surveillance colonoscopy

A kind of stool test

其他名称:
  • 细菌基因标记检测

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Sensitivity of bacterial gene markers panel (M3)
大体时间:1 month

The proportion of subjects with true positive results of M3 among those with one of more advanced neoplasia detected in the index colonoscopy.

1 month
Sensitivity of FIT/FOBT
大体时间:1 month

The proportion of subjects with true positive results of FIT among those with one of more advanced neoplasia detected in the index colonoscopy.

1 month

次要结果测量

结果测量
措施说明
大体时间
Sensitivity of M3 for early-stage (stage 1) or invasive (stage 2-4) colorectal cancers
大体时间:1 month

The proportion of subjects with true positive results of M3 among those with early-stage (stage 1) or invasive (stage 2-4) colorectal cancers detected in the index colonoscopy.

1 month
Sensitivity of FIT/FOBT for early-stage (stage 1) or invasive (stage 2-4) colorectal cancers
大体时间:1 month

The proportion of subjects with true positive results of FIT among those with early-stage (stage 1) or invasive (stage 2-4) colorectal cancers detected in the index colonoscopy.

1 month
Sensitivity of FIT/FOBT for advanced adenomas
大体时间:1 month

The proportion of subjects with true positive results of FIT among those with one or more advanced adenomas detected in the index colonoscopy.

1 month
Sensitivity of M3 for advanced adenomas
大体时间:1 month

The proportion of subjects with true positive results of M3 among those with one or more advanced adenomas detected in the index colonoscopy.

1 month
Sensitivity of FIT/FOBT for all adenomas
大体时间:1 month

The proportion of subjects with true positive results of FIT among those with all advanced adenomas detected in the index colonoscopy.

1 month
Sensitivity of M3 for all adenomas
大体时间:1 month

The proportion of subjects with true positive results of M3 among those with all advanced adenomas detected in the index colonoscopy.

1 month
Sensitivity of FIT/FOBT for sessile serrated lesions (SSL)
大体时间:1 month

The proportion of subjects with true positive results of FIT among those with SSLs detected in the index colonoscopy.

1 month
Sensitivity of M3 for sessile serrated lesions (SSL)
大体时间:1 month

The proportion of subjects with true positive results of M3 among those with SSLs detected in the index colonoscopy.

1 month
Specificity
大体时间:1 month

The proportion of true negative results of M3/FOBT/FIT among those with no adenoma detected in colonoscopy

1 month
Positive predictive value (PPV)
大体时间:1 month

The ratio of subjects truly diagnosed as positive to all those who had positive test results

1 month
Negative predictive value (NPV)
大体时间:1 month

The ratio of subjects truly diagnosed as negative to all those who had negative test results

1 month
Overall diagnostic accuracy
大体时间:1 month

The proportion of correctly classified subjects among all subjects

1 month
Microbiota changes in subjects with adenomas or normal findings after polypectomy
大体时间:1 month

Microbiota change measured by qPCR or metagenomic sequencing

1 month

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年6月29日

初级完成 (实际的)

2025年5月7日

研究完成 (估计的)

2030年12月31日

研究注册日期

首次提交

2022年6月1日

首先提交符合 QC 标准的

2022年6月1日

首次发布 (实际的)

2022年6月6日

研究记录更新

最后更新发布 (实际的)

2026年9月24日

上次提交的符合 QC 标准的更新

2026年9月21日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅